Verapamil but not calpain or creatine alters arsenate-induced cardiac cell death

Toxicology and Industrial Health

Volumn 25, Issue 3, 2009, Pages 169-176

  Luong, Mw ^a   Rabkin, Sw ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

arsenate; calpain; cell death; creatine; heart; verapamil

Indexed keywords

ACTIN; ARSENIC; ARSENIC ACID; CALPAIN; CALPASTATIN; CALPASTATIN 2; CREATININE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DAMAGE; CELL DEATH; CELL ISOLATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; HEART MUSCLE CELL; NONHUMAN;

ANIMALS; ARSENATES; CALPAIN; CELL DEATH; CHICK EMBRYO; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MYOCYTES, CARDIAC; OLIGOPEPTIDES; VERAPAMIL;

EID: 67149105783     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/0748233709105593     Document Type: Article

References (46)

1. Bae ON, Lim KM, Noh JY, Chung SM, Kim H, Lee CR (2007) Arsenite-enhanced procoagulant activity through phosphatidylserine exposure in platelets. Chem Res Toxicol 20: 1760–1768.
2. Belluck DA, Benjamin SL, Baveye P, Sampson J, Johnson B (2003) Widespread arsenic contamination of soils in residential areas and public spaces: an emerging regulatory or medical crisis? Int J Toxicol 22: 109–128.
3. Camins A, Verdaguer E, Folch J, Pallas M (2006) Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12: 135–148.
4. Carragher NO (2006) Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 12: 615–638.
5. Choudhary G, Dudley SC (2002) Heart failure, oxidative stress, and ion channel modulation. Congest Heart Fail 8: 148–155.
6. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910.
7. Cory JG, Cory AH, Lorico A, Rappa G, Sartorelli AC (1997) Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone. Anticancer Res 17: 3185–3193.
8. DeSesso JM, Jacobson CF, Scialli AR, Farr CH, Holson JF (1998) An assessment of the developmental toxicity of inorganic arsenic. Reprod Toxicol 12: 385–433.
9. Ditzel L, Stock D, Lowe J (1997) Structural investigation of proteasome inhibition. Biol Chem 378: 239–247.
10. Fernandez PA, Rotello RJ, Rangini Z, Doupe A, Drexler HC, Yuan J (1994) Expression of a specific marker of avian programmed cell death in both apoptosis and necrosis. Proc Natl Acad Sci U S A 91: 8641–8645.
11. Francesconi KA, Kuehnelt D (2004) Determination of arsenic species: a critical review of methods and applications, 2000–2003. Analyst 129: 373–395.
12. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83: 731–801.
13. Golstein P, Kroemer G (2007) Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 32: 37–43.
14. Gradecka D, Palus J, Wasowicz W (2001) Selected mechanisms of genotoxic effects of inorganic arsenic compounds. Int J Occup Med Environ Health 14: 317–328.
15. Hansford RG (1985) Relation between mitochondrial calcium transport and control of energy metabolism. Rev Physiol Biochem Pharmacol 102: 1–72.
16. Harwood SM, Yaqoob MM, Allen DA (2005) Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem 42: 415–431.
17. Huang RN, Lee TC (1996) Arsenite efflux is inhibited by verapamil, cyclosporin A, and GSH-depleting agents in arsenite-resistant Chinese hamster ovary cells. Toxicol Appl Pharmacol 141: 17–22.
18. Hughes MF (2002) Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133: 1–16.
19. Ibrahim D, Froberg B, Wolf A, Rusyniak DE (2006) Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med 26: 67–97.
20. Karlsson J, Pietras A, Beckman S, Pettersson HM, Larsson C, Pahlman S (2007) Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax. Oncogene 26: 6150–6159.
21. Kong JY, Rabkin SW (2002) Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am J Physiol Heart Circ Physiol 282: H717–H725.
22. Kong JY, Rabkin SW (2004) Reduction of palmitate-induced cardiac apoptosis by fenofibrate. Mol Cell Biochem 258: 1–13.
23. Kumagai Y, Sumi D (2007) Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol 47: 243–262.
24. Lantz RC, Hays AM (2006) Role of oxidative stress in arsenic-induced toxicity. Drug Metab Rev 38: 791–804.
25. Lee TC, Ko JL, Jan KY (1989) Differential cytotoxicity of sodium arsenite in human fibroblasts and Chinese hamster ovary cells. Toxicology 56: 289–299.
26. Lee PC, Ho IC, Lee TC (2005) Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci 85: 541–550.
27. Liu J, Waalkes M (2005) Focal adhesion kinase as a potential target in arsenic toxicity. Toxicol Sci 84: 212–213.
28. Liu YC, Huang H (1997) Involvement of calcium-dependent protein kinase C in arsenite-induced genotoxicity in Chinese hamster ovary cells. J Cell Biochem 64: 423–433.
29. Manna P, Sinha M, Sil PC (2008) Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch Toxicol 82: 137–149.
30. Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA (2005) Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 162: 1037–1049.
31. Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E (2006) Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114: 641–648.
32. Packman CH, Lichtman MA (1990) Activation of neutrophils: measurement of actin conformational changes by flow cytometry. Blood Cells 16: 193–205; discussion 205–197.
33. Pizarro I, Gomez MM, Fodor P, Palacios MA, Camara C (2004) Distribution and biotransformation of arsenic species in chicken cardiac and muscle tissues. Biol Trace Elem Res 99: 129–143.
34. Pryor WA; Lemercier JN; Zhang H; Uppu RM; Squadrito GL; (1997) The catalytic role of carbon dioxide in the decomposition of peroxynitrite. Free Radic Biol Med 23: 331–338 (Erratum appears in Free Radic Biol Med 1998; 24: 508).
35. Pulido MD, Parrish AR (2003) Metal-induced apoptosis: mechanisms. Mutat Res 533: 227–241.
36. Rabkin SW (1983) Interaction of external calcium concentration and verapamil on the effects of doxorubicin (adriamycin) in the isolated heart preparation. J Cardiovasc Pharmacol 5: 848–855.
37. Rabkin SW (1994) Effect of hypoxia on choline metabolism and phosphatidylcholine biosynthesis in isolated adult rat ventricular myocytes: effects of trifluoperazine. Biochem Cell Biol 72: 289–296.
38. Rabkin SW, Kong JY (2000a) Nifedipine does not induce but rather prevents apoptosis in cardiomyocytes. Eur J Pharmacol 388: 209–217.
39. Rabkin SW, Kong JY (2000b) Nitroprusside induces cardiomyocyte death: interaction with hydrogen peroxide. Am J Physiol Heart Circ Physiol 279: H3089–H3100.
40. Rabkin SW, Otten M, Polimeni PI (1983) Increased mortality with cardiotoxic doses of Adriamycin after verapamil pretreatment despite prevention of myocardial calcium accumulation. Can J Physiol Pharmacol 61: 1050–1056.
41. Sakaue M, Okazaki M, Hara S (2005) Very low levels of methylmercury induce cell death of cultured rat cerebellar neurons via calpain activation. Toxicology 213: 97–106.
42. Santella L, Kyozuka K, De Riso L, Carafoli E (1998) Calcium, protease action, and the regulation of the cell cycle. Cell Calcium 23: 123–130.
43. Tarnopolsky MA (2007) Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem 46: 183–204.
44. Vernhet L, Seite MP, Allain N, Guillouzo A, Fardel O (2001) Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J Pharmacol Exp Ther 298: 234–239.
45. Winski SL, Carter DE (1998) Arsenate toxicity in human erythrocytes: characterization of morphologic changes and determination of the mechanism of damage. J Toxicol Environ Health A 53: 345–355.
46. Wu MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Chen CJ (2001) Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109: 1011–1017.